Hypophosphatemia in critically ill adults and children - A systematic review.

Critical illness Hypophosphatemia Outcome Phosphate Prevalence Refeeding syndrome

Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
04 2021
Historique:
received: 07 08 2020
revised: 26 09 2020
accepted: 28 09 2020
pubmed: 4 12 2020
medline: 31 8 2021
entrez: 3 12 2020
Statut: ppublish

Résumé

Phosphate is the main intracellular anion essential for numerous biological processes. Symptoms of hypophosphatemia are non-specific, yet potentially life-threatening. This systematic review process was initiated to gain a global insight into hypophosphatemia, associated morbidity and treatments. A systematic review was conducted (PROSPERO CRD42020163191). Nine clinically relevant questions were generated, seven for adult and two for pediatric critically ill patients, and prevalence of hypophosphatemia was assessed in both groups. We identified trials through systematic searches of Medline, EMBASE, Scopus, Cochrane Central Register of Controlled Trials, CINAHL, and Web of Science. Quality assessment was performed using the Cochrane risk of bias tool for randomized controlled trials and the Newcastle-Ottawa Scale for observational studies. For all research questions, we identified 2727 titles in total, assessed 399 full texts, and retained 82 full texts for evidence synthesis, with 20 of them identified for several research questions. Only 3 randomized controlled trials were identified with two of them published only in abstract form, as well as 28 prospective and 31 retrospective studies, and 20 case reports. Relevant risk of bias regarding selection and comparability was identified for most of the studies. No meta-analysis could be performed. The prevalence of hypophosphatemia varied substantially in critically ill adults and children, but no study assessed consecutive admissions to intensive care. In both critically ill adults and children, several studies report that hypophosphatemia is associated with worse outcome (prolonged length of stay and the need for respiratory support, and higher mortality). However, there was insufficient evidence regarding the optimal threshold upon which hypophosphatemia becomes critical and requires treatment. We found no studies regarding the optimal frequency of phosphate measurements, and regarding the time window to correct hypophosphatemia. In adults, nutrient restriction on top of phosphate repletion in patients with refeeding syndrome may improve survival, although evidence is weak. Evidence on the definition, outcome and treatment of clinically relevant hypophosphatemia in critically ill adults and children is scarce and does not allow answering clinically relevant questions. High quality clinical research is crucial for the development of respective guidelines.

Sections du résumé

BACKGROUND & AIMS
Phosphate is the main intracellular anion essential for numerous biological processes. Symptoms of hypophosphatemia are non-specific, yet potentially life-threatening. This systematic review process was initiated to gain a global insight into hypophosphatemia, associated morbidity and treatments.
METHODS
A systematic review was conducted (PROSPERO CRD42020163191). Nine clinically relevant questions were generated, seven for adult and two for pediatric critically ill patients, and prevalence of hypophosphatemia was assessed in both groups. We identified trials through systematic searches of Medline, EMBASE, Scopus, Cochrane Central Register of Controlled Trials, CINAHL, and Web of Science. Quality assessment was performed using the Cochrane risk of bias tool for randomized controlled trials and the Newcastle-Ottawa Scale for observational studies.
RESULTS
For all research questions, we identified 2727 titles in total, assessed 399 full texts, and retained 82 full texts for evidence synthesis, with 20 of them identified for several research questions. Only 3 randomized controlled trials were identified with two of them published only in abstract form, as well as 28 prospective and 31 retrospective studies, and 20 case reports. Relevant risk of bias regarding selection and comparability was identified for most of the studies. No meta-analysis could be performed. The prevalence of hypophosphatemia varied substantially in critically ill adults and children, but no study assessed consecutive admissions to intensive care. In both critically ill adults and children, several studies report that hypophosphatemia is associated with worse outcome (prolonged length of stay and the need for respiratory support, and higher mortality). However, there was insufficient evidence regarding the optimal threshold upon which hypophosphatemia becomes critical and requires treatment. We found no studies regarding the optimal frequency of phosphate measurements, and regarding the time window to correct hypophosphatemia. In adults, nutrient restriction on top of phosphate repletion in patients with refeeding syndrome may improve survival, although evidence is weak.
CONCLUSIONS
Evidence on the definition, outcome and treatment of clinically relevant hypophosphatemia in critically ill adults and children is scarce and does not allow answering clinically relevant questions. High quality clinical research is crucial for the development of respective guidelines.

Identifiants

pubmed: 33268142
pii: S0261-5614(20)30517-3
doi: 10.1016/j.clnu.2020.09.045
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1744-1754

Informations de copyright

Copyright © 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest None of the co-authors has any competing interest to declare regarding the present systematic review.

Auteurs

Annika Reintam Blaser (A)

Department of Anaesthesiology and Intensive Care, University of Tartu, Estonia; Department of Intensive Care Medicine, Lucerne Cantonal Hospital, Lucerne, Switzerland. Electronic address: annika.reintam.blaser@ut.ee.

Jan Gunst (J)

Clinical Department and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium. Electronic address: jan.gunst@kuleuven.be.

Carole Ichai (C)

Mixed Intensive Care Unit, Université Côte d'Azur, Nice, France. Electronic address: ichai@unice.fr.

Michael P Casaer (MP)

Clinical Department and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium. Electronic address: Michael.casaer@uzleuven.be.

Carina Benstoem (C)

Department of Intensive Care Medicine, Medical Faculty RWTH Aachen, Aachen, Germany. Electronic address: cbenstoem@ukaachen.de.

Guillaume Besch (G)

Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, Besancon, France. Electronic address: gbesch@chu-besancon.fr.

Stéphane Dauger (S)

Pediatric Intensive Care Unit, Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address: stephane.dauger@aphp.fr.

Sonja M Fruhwald (SM)

Department of Anesthesiology and Intensive Care Medicine, Division of Anesthesiology for Cardiovascular Surgery and Intensive Care Medicine, Medical University of Graz, Graz, Austria. Electronic address: sonja.fruhwald@medunigraz.at.

Michael Hiesmayr (M)

Cardiac Thoracic Vascular Anaesthesia and Intensive Care, Medical University Vienna, Waehringerguertel 18-20, 1090 Vienna, Austria. Electronic address: michael.hiesmayr@meduniwien.ac.at.

Olivier Joannes-Boyau (O)

Service d'Anesthésie-Réanimation SUD, Hôpital Magellan, CHU de Bordeaux, Bordeaux, France. Electronic address: olivier.joannes-boyau@chu-bordeaux.fr.

Manu L N G Malbrain (MLNG)

Department Intensive Care Medicine, University Hospital Brussel (UZB), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Jette, Brussels, Belgium. Electronic address: Manu.Malbrain@telenet.be.

Maria-Helena Perez (MH)

Paediatric Intensive Care Unit, Department of Paediatrics, Division Women-Mother-Child, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: marie-helene.perez@chuv.ch.

Stefan J Schaller (SJ)

Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Anesthesiology and Operative Intensive Care Medicine, Berlin, Germany. Electronic address: stefan.schaller@charite.de.

Angelique de Man (A)

Amsterdam UMC, Location VUMC, Amsterdam, the Netherlands. Electronic address: ame.deman@amsterdamumc.nl.

Joel Starkopf (J)

Department of Anaesthesiology and Intensive Care, Tartu University Hospital, University of Tartu, Estonia. Electronic address: Joel.Starkopf@kliinikum.ee.

Kadri Tamme (K)

Department of Anaesthesiology and Intensive Care, Tartu University Hospital, University of Tartu, Estonia. Electronic address: Kadri.Tamme@kliinikum.ee.

Jan Wernerman (J)

Department of Perioperative Medicine, Karolinska University Hospital Huddinge, CLINTEC Karolinska Institutet, Stockholm, Sweden. Electronic address: jan.wernerman@sll.se.

Mette M Berger (MM)

Service of Adult Intensive care & Burns, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: mette.berger@chuv.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH